Andrew Cheng net worth and biography

Andrew Cheng Biography and Net Worth

Dr. Andrew Cheng joined Akero in September, 2018, as President and Chief Executive Officer. Prior to joining Akero, Andrew served Gilead Sciences’ Senior Vice President from 2009-2015, then became Executive Vice President and Chief Medical Officer, during which time, he was responsible for the clinical development for the HIV program resulting in 11 FDA/EMA approved products. His past responsibilities also included medical affairs and the creation of the development operations department (regulatory affairs, clinical operations, pharmacovigilance, project management, clinical pharmacology, and biometrics), which covered clinical development support in multiple therapeutic areas including oncology, inflammation, respiratory, cardiovascular, HIV, and liver diseases.

Andrew previously served on the board of directors of Syntimmune, Inc., which was acquired by Alexion, and in August 2019, joined the board of directors of Arbutus Biopharma Corporation. He holds a BA in biology from Johns Hopkins University, and an MD and PhD in cellular and molecular biology from Columbia University College of Physicians and Surgeons. He completed his internal medicine residency at UCLA, and was board certified in internal medicine.

What is Andrew Cheng's net worth?

The estimated net worth of Andrew Cheng is at least $17.79 million as of February 1st, 2023. Dr. Cheng owns 370,999 shares of Akero Therapeutics stock worth more than $17,793,112 as of February 5th. This net worth estimate does not reflect any other investments that Dr. Cheng may own. Learn More about Andrew Cheng's net worth.

How do I contact Andrew Cheng?

The corporate mailing address for Dr. Cheng and other Akero Therapeutics executives is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. Akero Therapeutics can also be reached via phone at (650) 487-6488 and via email at [email protected] Learn More on Andrew Cheng's contact information.

Has Andrew Cheng been buying or selling shares of Akero Therapeutics?

Over the course of the past ninety days, Andrew Cheng has sold $2,508,250.00 in Akero Therapeutics stock. Most recently, Andrew Cheng sold 25,000 shares of the business's stock in a transaction on Wednesday, February 1st. The shares were sold at an average price of $49.06, for a transaction totalling $1,226,500.00. Following the completion of the sale, the chief executive officer now directly owns 370,999 shares of the company's stock, valued at $18,201,210.94. Learn More on Andrew Cheng's trading history.

Who are Akero Therapeutics' active insiders?

Akero Therapeutics' insider roster includes Kevin Bitterman (Director), Andrew Cheng (CEO), William White (CFO), Catriona Yale (Insider), and Jonathan Young (COO). Learn More on Akero Therapeutics' active insiders.

Are insiders buying or selling shares of Akero Therapeutics?

During the last twelve months, insiders at the sold shares 27 times. They sold a total of 2,098,309 shares worth more than $88,606,056.33. The most recent insider tranaction occured on February, 1st when CEO Andrew Cheng sold 25,000 shares worth more than $1,226,500.00. Insiders at Akero Therapeutics own 10.4% of the company. Learn More about insider trades at Akero Therapeutics.

Information on this page was last updated on 2/1/2023.

Andrew Cheng Insider Trading History at Akero Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/1/2023Sell25,000$49.06$1,226,500.00370,999View SEC Filing Icon  
1/3/2023Sell25,000$51.27$1,281,750.00370,999View SEC Filing Icon  
12/1/2022Sell10,000$46.07$460,700.00310,148View SEC Filing Icon  
11/1/2022Sell10,000$43.42$434,200.00310,148View SEC Filing Icon  
10/3/2022Sell10,000$33.23$332,300.00310,148View SEC Filing Icon  
9/13/2022Sell60,000$27.42$1,645,200.00310,148View SEC Filing Icon  
3/1/2022Sell10,000$17.59$175,900.00View SEC Filing Icon  
2/1/2022Sell10,000$17.56$175,600.00View SEC Filing Icon  
1/10/2022Sell10,000$19.55$195,500.00View SEC Filing Icon  
8/3/2021Sell17,500$20.83$364,525.00View SEC Filing Icon  
7/2/2021Sell17,500$24.78$433,650.00View SEC Filing Icon  
See Full Table

Andrew Cheng Buying and Selling Activity at Akero Therapeutics

This chart shows Andrew Cheng's buying and selling at Akero Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Akero Therapeutics Company Overview

Akero Therapeutics logo
Akero Therapeutics, Inc. operates as a cardio-metabolic nonalcoholic steatohepatitis company, which engages in developing pioneering medicines designed to restore metabolic balance and improve overall health. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $47.96
Low: $46.50
High: $49.28

50 Day Range

MA: $46.84
Low: $38.78
High: $54.80

2 Week Range

Now: $47.96
Low: $7.52
High: $54.88


337,336 shs

Average Volume

534,885 shs

Market Capitalization

$2.24 billion

P/E Ratio


Dividend Yield